Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rubicon Medical (RMDC) -- Ignore unavailable to you. Want to Upgrade?

To: Prospector who wrote (9)	11/16/2001 9:24:50 PM
From: Prospector	Respond to of 10

The Guardian is a patented technology for primary use in the neurointerventional and cardiology markets. The total worldwide neurointerventional market is approximately 260,000 procedures or $195,000,000 with high anticipated growth rates. 3 The global 4 cardiology market for the Guardian is $451,014,000 or 601,352 procedures. This brings the total market for the Guardian system to over $646,000,000. It is reasonable to expect that a major marketing partner can capture 10% of the worldwide market for this patented technology. In addition to the primary markets of neuro?interventional and cardiology, additional secondary markets in peripheral medicine are not fully understood. The technology is so new, physicians are exploring more uses and therapies where the Guardian can be clinically useful